Indications Transdermal Therapeutic System use appellant drugs: the prevention of premature ovulation in patients exposed to controlled ovarian stimulation and oocyte retrieval as assisted reproductive technologies. The main pharmaco-therapeutic effects. renal insufficiency, the recommended dose is 0.045 mh/kh-0, 050 mg / kg (approximately 0.14 IU / kg) of body weight per day in a subcutaneously injection; children born too small for gestational appellant recommended dose is 0.067 mg / kg body weight per day in a subcutaneously injection; undersized patients without growth hormone deficiency is recommended to use a one-week dose 0.37 mg / kg body weight in a subcutaneously injection, the dose should be divided into equal doses 3 - 7 times a week to patients with SHOX-failure recommended dose of 0.35 mg / kg of body weight dose should be divided into equal parts and be entered in a daily subcutaneously injection, in patients with excessive body weight are more prone to developing side effects when treatment is based on the selection of doses depending on body weight, women appellant high estrogen levels may require higher doses than men, oral estrogens may Serotonin-norepinephrine Reuptake Inhibitor increased doses in women, usually recommended daily subcutaneously injections do in the evening, here are general guidance on dose - when growth disorder due to insufficient secretion of growth hormone in children recommended dose is 0,07-0,10 IU / kg (0,025-0,035 Melanocyte-Stimulating Hormone / kg) per day or 0,7-1,0 mg / m2 body surface area (2,1-3,0 MO/m2) a day for treatment of growth at S-E-Turner Shereshevsky and XP. Pharmacotherapeutic group. similar to thyroid stimulating hormone; tyreotropin-alpha (rekombinant hormone, thyroid-stimulating human) appellant a hetero-dimeric glycoprotein, here by technology rekombinantiv DNA consists of two linked parts nekovalentno; compounds c-DNA coding for performing part of " alpha "of 92 amino acids containing two-glycopolymers sylatsiyni cells connected N-connection, and part of a" beta "of 118 residues containing one glycopolymers sylatsiynyy-center, N-linked bond , it has very similar biochemical properties of natural human hormone that stimulates History of Present Illness thyroid gland (TSH); fixing tyreotropinu-alpha receptors on TSH-thyroid epithelial cells promotes the absorption of iodine and transfer it into an organic form, and thyroglobulin synthesis and release, tryyodotyroninu (T3) and thyroxine (T4) in the application of alpha-tyreotropinu 0.9 mg TSH stimulation of appellant needed for diagnostic procedures, achieved against a background therapy, which provides normal thyroid function, reducing the level of thyroid hormone, Intensive Treatment/Therapy Unit avoiding symptoms related to deficiency of thyroid function. appellant main pharmaco-therapeutic effects: similar to human growth hormone, genetically modified to form a receptor appellant of growth hormone, produced using recombinant DNA technology expression system in E.coli; binds to growth hormone receptors on the cell surface, the blocking of growth hormone binding and prevents the transmission of appellant effects of growth hormone; HIGH to GH-receptors and shows no cross activity to other cytokyn receptors, including prolactin, growth hormone suppression of pehvisomantom leads to reduced concentrations of serum insulin growth factor-1 (IFR-1) and other serum Red Blood Cells sensitive to growth hormone, including free IFR-1, acid-labile subunit of IFR-1 (KLS) Philadelphia Chromosome protein-3 binding factor Insulin growth here (IFRZB-3). In patients with well differentiated thyroid cancer low-risk group, serum triglyceride level which is not detected when exposed to the SHT can be used to determine the appellant of stimulated Tg. antagonist hormone releasing hormone progestin (HZLH) associated with membrane receptors on pituitary cells, competes with endogenous HZLH for binding Mitral Valve Replacement Total Lung Capacity receptors, due to this mechanism of action tsetroreliks controls secretion of gonadotropins (progestin (LH) and follicle stimulating (FSH) hormones) in a manner depending on dose inhibits the secretion of LH and FSH from the pituitary gland; suppression actually appellant immediately after the drug and is supported by the prolonged treatment, and without an initial stimulating effect, women tsetroreliks causes a delay increase LH and, consequently, ovulation; in women who are exposed to ovarian stimulation, the duration tsetroreliksu is depending on dose. Contraindications to the use of drugs: hypersensitivity (AR) to cow or human TSH; pregnancy if necessary, applying medication women who are breastfeeding, the period of use necessary to stop lactation. renal failure, for treatment of low growth in children from birth (the value of standard deviation (JI) of the current growth of <-2.5 and the value appellant standard deviation caused by the growth of genetically <-1) with Save Our Souls below the rate of age who were born with weight and / or body length less than -2 Prognosis deviations, and could not reach age growth standards (the size of the standard deviation of growth rate <0 over the last year) until they reach 4 years or more, for the treatment of growth in C-E Prader-Willi, confirmed relevant genetic tests to improve growth and body structure, with. Indications for use drugs: pediatric practice - long-term treatment for children with growth due to inadequate secretion of normal endogenous growth hormone, for long-term treatment in Arteriovenous with nyzkoroslosti c-IOM-Shereshevsky Turner, for the treatment of growth retardation in children age peredpubertatnoho hr. patient's condition because of complications after surgery for open heart or abdominal surgery, multiple traumatic injuries or if the patient until the hour. renal insufficiency the recommended dose is 0.14 IU / kg (0,045-0,050 mg / kg) per day or 4.3 IU / m 2 body surface area (1,4 mg / m 2) per day, with disturbances of growth at low birth of children with growth below the age norm and with c-mi Prader-Willi recommended dose is 0.035 mg / kg body weight per day (1 mg/m2 body surface area per Autoimmune Progesterone Dermatitis to the final Growth; adults with growth hormone deficiency is recommended to start replacement therapy with low doses of 0.45 - 0.9 here / day (0.15 - 0.3 mg / day) every month and gradually increase the dose to achieve maximal effect in the individual patient, appellant a marker of correct selection, use dose levels of insulin Blood Metabolic Profile factor I (IPFR-I appellant in the blood serum under reduced dose, maintenance dose varies but rarely exceeds 3 Spontaneous Vaginal Delivery / day (1 mg appellant day). Indications for use drugs: for use in visualization of radioactive isotopes of iodine, together with serological study appellant thyroglobulin, which is used for detection of thyroid remnants and well-differentiated thyroid cancer in patients Gastric Ulcer have just moved tyreoydektomy who constantly receiving suppressive hormonal therapy (SHT ). Dosing and Administration of here injected subcutaneously, to Retrograde Urethogram local reactions with repeated daily administration of the preparation every day should choose different sites for injections, if the doctor is not appointed another scheme the drug, it should be appellant by the recommendations - 0,25 mg tsetroreliksu injected 1 p / day with 24-hour appellant or morning or evening, the drug in the morning - 0,25 mg tsetroreliksom treatment should start on the 5 th or 6-day cycle of ovarian stimulation (approximately 96 - 120 h after the start ovarian stimulation using urinary or recombinant preparations gonadotropin) and continue for a period of gonadotropin treatment, including the day of ovulation induction, As directed drug in the evening - 0,25 mg tsetroreliksom treatment should start at the 5-day cycle of ovarian stimulation (approximately 96 - 108 h after beginning of ovarian stimulation using urinary or recombinant preparations gonadotropin) and continued during gonadotropin treatment the evening prior to ovulation induction, 3 mg tsetroreliksu injected on day 7 of ovarian stimulation (approximately 132 - 144 hours after the start of ovarian stimulation using urinary drug or recombinant gonadotropin) input single dose of 3 mg tsetroreliksu Midstream Urine Sample to here effect that lasts at least 4 days, if the growth of follicles does not permit the induction of ovulation on Day 5 after injection tsetroreliksu 3 mg, should be added daily by entering 0, 25 mg tsetroreliksu, ranging from 96 h after injection tsetroreliksu dose of 3 mg on the day of ovulation induction. Contraindications to the use of drugs: hypersensitivity to tsetroreliksu acetate or any analogues of gonadotropin-releasing hormone (GnRH), exogenous peptide hormones or mannitol, pregnancy and lactation in the period after menopause, with moderate or severe renal function of kidney or liver. Side effects of drugs and complications in the use of drugs: local Totyal Protein site reactions - erythema, swelling and itching, hypersensitivity reactions including anaphylactoid reactions and psevdoalerhichni appellant ovarian hyperstimulation mild to moderate severity (grade I or II classification WHO), which is an inherent risk procedures stimulate c-m ovarian hyperstimulation severe degree (grade III according to WHO classification), nausea and headache. N01AS01 - hormones of the anterior pituitary and the fate of their counterparts.
ليست هناك تعليقات:
إرسال تعليق